Table 2.
Antimyeloma standard of care therapy.
| SOC treatment, n (%)a | N = 248 |
|---|---|
| Glucocorticoid | 220 (88.7) |
| PI | 133 (53.6) |
| Carfilzomib | 63 (25.4) |
| Bortezomib | 48 (19.4) |
| Ixazomib | 22 (8.9) |
| IMiD | 117 (47.2) |
| Pomalidomide | 74 (29.8) |
| Lenalidomide | 36 (14.5) |
| Thalidomide | 7 (2.8) |
| Alkylating agent | 107 (43.1) |
| Cyclophosphamide | 79 (31.9) |
| Bendamustine | 16 (6.5) |
| Melphalan | 15 (6.0) |
| Anti-CD38 monoclonal antibody | 24 (9.7) |
| Daratumumab | 23 (9.3) |
| Isatuximab | 1 (0.4) |
| Anthracyclines | 18 (7.3) |
| Topoisomerase inhibitor | 16 (6.5) |
| Other antineoplastic agentb | 15 (6.0) |
| Histone deacetylase inhibitor | 12 (4.8) |
| Anti-SLAMF7 monoclonal antibody | 9 (3.6) |
| BCMA-targeted antibody-drug conjugate | 7 (2.8) |
| Bcl-2 inhibitor | 6 (2.4) |
| Autologous stem cell transplant | 6 (2.4) |
| Mitotic inhibitor | 2 (0.8) |
| Selective inhibitor of nuclear export | 2 (0.8) |
BCMA B-cell maturation antigen, Bcl B-cell lymphoma, IMiD immunomodulatory drug, PI proteasome inhibitor, SLAM signaling lymphocytic activation molecule, SOC standard of care.
aThere was a large amount of heterogeneity in the combination therapies. Patients may have been counted in more than one regimen.
bOther antineoplastic agents included cisplatin and rituximab.